Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

• ≥18 years old

• Histopathological examination of the primary biopsy confirmed the diagnosis oflocally advanced esophageal squamous cell carcinoma

• At least one measurable lesion

• Eastern cooperative oncology group (ECOG) performance status of 0 to 1

• With adequate organs function

Exclusion Criteria:

• Patients with active malignancy within 5 years other than the tumor studied in thisstudy or a localized tumor that has been cured such as resected basal or squamouscell carcinoma, superficial bladder cancer, cervical carcinoma in situ, or breastcancer

• Patients who have a higher risk of bleeding or perforation due to the tumor'sobvious invasion of the adjacent organs (aorta or trachea) of the esophageal lesion,or patients who have formed a fistula

• Patients who have received any anti-tumor therapy for the research disease in thepast, including radiotherapy, chemotherapy, immunotherapy (including but not limitedto interleukin, interferon, thymus hormone) and traditional Chinese medicine therapy